Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Antidotes Stories

2012-02-28 06:00:00

RALEIGH, N.C., Feb. 28, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the development program for BEMA Buprenorphine/Naloxone (BNX) that should result in a New Drug Application (NDA) filing for the treatment of opioid dependence in the first half of 2013. BDSI recently met with the FDA and discussed the results of its recently completed pharmacokinetic study...

2012-02-08 15:20:00

NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote® (acetylcysteine) Injection, which is used to treat acetaminophen poisoning. The new formulation was FDA approved in 2011 and listed in the "Orange Book," the FDA's official register of approved pharmaceutical products. Once issued,...

2012-02-08 11:05:00

NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012. A conference call and live Internet webcast will be held on Wednesday, February 29, 2012, at 5:00 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of...

2011-12-20 15:22:00

RALEIGH, N.C., Dec. 20, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced results from its confirmatory study, BNX-102, assessing the pharmacokinetics of its BEMA Buprenorphine/Naloxone (BNX) formulation compared to Suboxone. The results confirm the final formulation and provide the basis for moving forward into the pivotal comparative pharmacokinetic study versus Suboxone. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )...

2011-11-26 08:00:00

Pureness Bird's Nest, http://www.purenessbirdnest.com.sg, has successful collaborated with the worldâs renowned edible birdâs nest researcher and consultant in Malaysia, Dr Tan Boon Siong to produce nitrite free edible birdâs nest. Asia, Singapore (PRWEB) November 26, 2011 Pureness Birdâs Nest, a leading birdâs nest researcher and birdâs nest education company based in Singapore has successful collaborated with...

Milk Thistle Stops Lung Cancer In Mice
2011-11-16 04:32:58

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis. Though the natural extract has been used for more than 2,000 years, mostly to treat disorders of the liver and gallbladder, this is one...

2011-11-10 06:00:00

RALEIGH, N.C., Nov. 10, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that it has initiated a confirmatory pharmacokinetic study of a formulation of buprenorphine and naloxone utilizing BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) The study, BNX-102, will be used to select the final doses of BEMA Buprenorphine/Naloxone to be used in the pivotal...

2011-08-31 11:41:00

NASHVILLE, Tenn., Aug. 31, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 19, 2011, at 8:00 a.m. Eastern Time. The presentation will be simultaneously webcast and can be accessed through the Investor Relations section of...

2011-06-28 08:51:00

PRAGUE, June 28, 2011 /PRNewswire/ -- The 48th ERA-EDTA congress was the setting for a wide range of new clinical data. The "Late-Breaking Clinical Trials" were met with particular interest, one of them being the IMPACT SHPT study (Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D). In the oral presentation on 25 June the principal investigator of this study, Prof. Markus Ketteler (Coburg, Germany), summarized the final data, whereas the...

2011-04-22 05:45:00

NASHVILLE, Tenn., April 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release first quarter 2011 financial results after the market closes on Wednesday, May 4, 2011. A conference call and live Internet webcast will be held on Wednesday, May 4, 2011 at 5:00 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the...